Oxidative and nitrative stress in neurodegeneration

Neurobiology of Disease

Volumn 84, Issue , 2015, Pages 4-21

  Cobb, Catherine A ^a   Cole, Marsha P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Brain; Dopamine metabolism; Lipid peroxidation; Lipid protein modification; Microglial activation; Neurodegeneration; Nitrative stress; Oxidative stress; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN; HYDROGEN PEROXIDE; MALONALDEHYDE; NITRIC OXIDE; PEROXYNITRITE; POLYUNSATURATED FATTY ACID; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; XANTHINE OXIDASE;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CELL ACTIVATION; CELLULAR DETOXIFICATION; CELLULAR PARAMETERS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE METABOLISM; EPILEPSY; HUMAN; HUNTINGTON CHOREA; LIPID NITRATION; LIPID PEROXIDATION; MEMBRANE FLUIDITY; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NITRATION; NITRATIVE STRESS; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL DIABETIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN NITRATION; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DEGENERATIVE DISEASE; METABOLISM; PHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 84930749500     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.04.020     Document Type: Review

References (156)

1. Ali T.K., Matragoon S., Pillai B.A., Liou G.I., El-Remessy A.B. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes 2008, 57:889-898.
2. Allen A.T., Maher K.N., Wani K.A., Betts K.E., Chase D.L. Coexpressed D1- and D2-like dopamine receptors antagonistically modulate acetylcholine release in Caenorhabditis elegans. Genetics 2011, 188:579-590.
3. Ara J., Przedborski S., Naini A.B., Jackson-Lewis V., Trifiletti R.R., Horwitz J., Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7659-7663.
4. Ayala A., Munoz M.F., Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Med. Cell. Longev. 2014, 2014:360438.
5. Bajo-Graneras R., Ganfornina M.D., Martin-Tejedor E., Sanchez D. Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems. Glia 2011, 59:1551-1566.
6. Baker L.M., Baker P.R., Golin-Bisello F., Schopfer F.J., Fink M., Woodcock S.R., Branchaud B.P., Radi R., Freeman B.A. Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. J. Biol. Chem. 2007, 282:31085-31093.
7. Bal-Price A., Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. Off. J. Soc. Neurosci. 2001, 21:6480-6491.
8. Belluzzi E., Bisaglia M., Lazzarini E., Tabares L.C., Beltramini M., Bubacco L. Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLoS One 2012, 7:e38026.
9. Bisaglia M., Filograna R., Beltramini M., Bubacco L. Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?. Ageing Res. Rev. 2014, 13:107-114.
10. Biscaro B., Lindvall O., Tesco G., Ekdahl C.T., Nitsch R.M. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener. Dis. 2012, 9:187-198.
11. Bjork L., Jenkins N.T., Witkowski S., Hagberg J.M. Nitro-oxidative stress biomarkers in active and inactive men. Int. J. Sports Med. 2012, 33:279-284.
12. Blochl A., Sirrenberg C. Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. J. Biol. Chem. 1996, 271:21100-21107.
13. Bonacci G., Baker P.R., Salvatore S.R., Shores D., Khoo N.K., Koenitzer J.R., Vitturi D.A., Woodcock S.R., Golin-Bisello F., Cole M.P., Watkins S., St Croix C., Batthyany C.I., Freeman B.A., Schopfer F.J. Conjugated linoleic acid is a preferential substrate for fatty acid nitration. J. Biol. Chem. 2012, 287:44071-44082.
14. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41:242-247.
15. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. (Zurich Switz.) 1999, 9:147-163.
16. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125:1297-1308.
17. Cai Z., Lin S., Fan L.W., Pang Y., Rhodes P.G. Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience 2006, 137:425-435.
18. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
19. Cepeda C., Cummings D.M., Andre V.M., Holley S.M., Levine M.S. Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro 2010, 2:e00033.
20. Chandramani Shivalingappa P., Jin H., Anantharam V., Kanthasamy A., Kanthasamy A. N-Acetyl cysteine protects against methamphetamine-induced dopaminergic neurodegeneration via modulation of redox status and autophagy in dopaminergic cells. Park. Dis. 2012, 424285.
21. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013, 108:21-43.
22. Chen C.M., Wu Y.R., Cheng M.L., Liu J.L., Lee Y.M., Lee P.W., Soong B.W., Chiu D.T. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 2007, 359:335-340.
23. Chen Y.J., Ching W.C., Lin Y.P., Chen Y.J. Methods for detection and characterization of protein S-nitrosylation. Methods (San Diego Calif.) 2013, 62:138-150.
24. Chiarugi A. Intrinsic mechanisms of poly(ADP-ribose) neurotoxicity: three hypotheses. Neurotoxicology 2005, 26:847-855.
25. Cho K.J., Kim H.W., Cheon S.Y., Lee J.E., Kim G.W. Apoptosis signal-regulating kinase-1 aggravates ROS-mediated striatal degeneration in 3-nitropropionic acid-infused mice. Biochem. Biophys. Res. Commun. 2013, 441:280-285.
26. Choi D.K., Koppula S., Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules (Basel Switz.) 2011, 16:1021-1043.
27. Chung K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C., Marsh L., Dawson V.L., Dawson T.M. S-Nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (N.Y. NY) 2004, 304:1328-1331.
28. Chung E.S., Chung Y.C., Bok E., Baik H.H., Park E.S., Park J.Y., Yoon S.H., Jin B.K. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res. 2010, 1363:143-150.
29. Crabb J.W., O'Neil J., Miyagi M., West K., Hoff H.F. Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues. Protein Sci. 2002, 11:831-840.
30. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
31. Dajas-Bailador F., Costa G., Emmett S., Bonilla C., Dajas F. Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo. Brain Res. 1996, 722:12-18.
32. Dassati S., Waldner A., Schweigreiter R. Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain. Neurobiol. Aging 2014, 35:1632-1642.
33. David M.A., Tayebi M. Detection of protein aggregates in brain and cerebrospinal fluid derived from multiple sclerosis patients. Front. Neurol. 2014, 5:251.
34. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011, 18:21-29.
35. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14669-14674.
36. Duarte A.I., Candeias E., Correia S.C., Santos R.X., Carvalho C., Cardoso S., Placido A., Santos M.S., Oliveira C.R., Moreira P.I. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim. Biophys. Acta 2013, 1832:527-541.
37. Farber K., Pannasch U., Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell. Neurosci. 2005, 29:128-138.
38. Fazzari M., Trostchansky A., Schopfer F.J., Salvatore S.R., Sanchez-Calvo B., Vitturi D., Valderrama R., Barroso J.B., Radi R., Freeman B.A., Rubbo H. Olives and olive oil are sources of electrophilic fatty acid nitroalkenes. PLoS One 2014, 9:e84884.
39. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66:137-147.
40. Franco M.C., Ye Y., Refakis C.A., Feldman J.L., Stokes A.L., Basso M., Melero Fernandez de Mera R.M., Sparrow N.A., Calingasan N.Y., Kiaei M., Rhoads T.W., Ma T.C., Grumet M., Barnes S., Beal M.F., Beckman J.S., Mehl R., Estevez A.G. Nitration of Hsp90 induces cell death. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1102-E1111.
41. Freeman B.A., Baker P.R., Schopfer F.J., Woodcock S.R., Napolitano A., d'Ischia M. Nitro-fatty acid formation and signaling. J. Biol. Chem. 2008, 283:15515-15519.
42. Friend D.M., Fricks-Gleason A.N., Keefe K.A. Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration?. Neurotox. Res. 2014, 25:153-160.
43. Ganfornina M.D., Do Carmo S., Lora J.M., Torres-Schumann S., Vogel M., Allhorn M., Gonzalez C., Bastiani M.J., Rassart E., Sanchez D. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging cell 2008, 7:506-515.
44. Granado N., Ares-Santos S., Moratalla R. Methamphetamine and Parkinson's disease. Park. Dis. 2013, 308052.
45. Greferath U., Mallard C., Roufail E., Rees S.M., Barrett G.L., Bartlett P.F. Expression of the p75 neurotrophin receptor by striatal cholinergic neurons following global ischemia in rats is associated with neuronal degeneration. Neurosci. Lett. 2002, 332:57-60.
46. Greilberger J., Koidl C., Greilberger M., Lamprecht M., Schroecksnadel K., Leblhuber F., Fuchs D., Oettl K. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic. Res. 2008, 42:633-638.
47. Gupta N., Yucel Y.H. Glaucoma as a neurodegenerative disease. Curr. Opin. Ophthalmol. 2007, 18:110-114.
48. Haider L., Fischer M.T., Frischer J.M., Bauer J., Hoftberger R., Botond G., Esterbauer H., Binder C.J., Witztum J.L., Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
49. Haider L., Simeonidou C., Steinberger G., Hametner S., Grigoriadis N., Deretzi G., Kovacs G.G., Kutzelnigg A., Lassmann H., Frischer J.M. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J. Neurol. Neurosurg. Psychiatry 2014, 85:1386-1395.
50. Hanson A.J., Prasad J.E., Nahreini P., Andreatta C., Kumar B., Yan X.D., Prasad K.N. Overexpression of amyloid precursor protein is associated with degeneration, decreased viability, and increased damage caused by neurotoxins (prostaglandins A1 and E2, hydrogen peroxide, and nitric oxide) in differentiated neuroblastoma cells. J. Neurosci. Res. 2003, 74:148-159.
51. Hautanen A., Manttari M., Manninen V., Adlercreutz H. Gemfibrozil treatment is associated with elevated adrenal androgen, androstanediol glucuronide and cortisol levels in dyslipidemic men. J. Steroid Biochem. Mol. Biol. 1994, 51:307-313.
52. He X., Jittiwat J., Kim J.H., Jenner A.M., Farooqui A.A., Patel S.C., Ong W.Y. Apolipoprotein D modulates F2-isoprostane and 7-ketocholesterol formation and has a neuroprotective effect on organotypic hippocampal cultures after kainate-induced excitotoxic injury. Neurosci. Lett. 2009, 455:183-186.
53. Hogg N., Kalyanaraman B. Nitric oxide and lipid peroxidation. Biochim. Biophys. Acta 1999, 1411:378-384.
54. Hu L.F., Lu M., Tiong C.X., Dawe G.S., Hu G., Bian J.S. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging cell 2010, 9:135-146.
55. Hurley L.L., Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox. Res. 2013, 23:131-144.
56. Inman D.M., Lambert W.S., Calkins D.J., Horner P.J. Alpha-lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS One 2013, 8:e65389.
57. Itzhak Y., Martin J.L., Ali S.F. Methamphetamine- and 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice. Synapse (N. Y. NY) 1999, 34:305-312.
58. Jing Y.H., Chen K.H., Kuo P.C., Pao C.C., Chen J.K. Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol. Neuroendocrinology 2013, 98:116-127.
59. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
60. Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino Acids 2004, 26:243-254.
61. Kauppinen T.M., Suh S.W., Higashi Y., Berman A.E., Escartin C., Won S.J., Wang C., Cho S.H., Gan L., Swanson R.A. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid beta. J. Neuroinflammation 2011, 8:152.
62. Khan M.M., Ahmad A., Ishrat T., Khan M.B., Hoda M.N., Khuwaja G., Raza S.S., Khan A., Javed H., Vaibhav K., Islam F. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010, 1328:139-151.
63. Kim M.Y., Zhang T., Kraus W.L. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev. 2005, 19:1951-1967.
64. Kim H.G., Moon M., Choi J.G., Park G., Kim A.J., Hur J., Lee K.T., Oh M.S. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 2014, 40:23-32.
65. Kita T., Asanuma M., Miyazaki I., Takeshima M. Protective effects of phytochemical antioxidants against neurotoxin-induced degeneration of dopaminergic neurons. J. Pharmacol. Sci. 2014, 124:313-319.
66. Kokaia Z., Andsberg G., Martinez-Serrano A., Lindvall O. Focal cerebral ischemia in rats induces expression of P75 neurotrophin receptor in resistant striatal cholinergic neurons. Neuroscience 1998, 84:1113-1125.
67. Kono Y. The production of nitrating species by the reaction between nitrite and hypochlorous acid. Biochem. Mol. Biol. Int. 1995, 36:275-283.
68. Korolchuk V.I., Rubinsztein D.C. Regulation of autophagy by lysosomal positioning. Autophagy 2011, 7:927-928.
69. Kraemer B.R., Snow J.P., Vollbrecht P., Pathak A., Valentine W.M., Deutch A.Y., Carter B.D. A role for the p75 neurotrophin receptor in axonal degeneration and apoptosis induced by oxidative stress. J. Biol. Chem. 2014, 289:21205-21216.
70. Kriscenski-Perry E., Durham H.D., Sheu S.S., Figlewicz D.A. Synergistic effects of low level stressors in an oxidative damage model of spinal motor neuron degeneration. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2002, 3:151-157.
71. Kuhn D.M., Francescutti-Verbeem D.M., Thomas D.M. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N. Y. Acad. Sci. 2006, 1074:31-41.
72. Lee Y., Kim Y.H., Park S.J., Huh J.W., Kim S.H., Kim S.U., Kim J.S., Jeong K.J., Lee K.M., Hong Y., Lee S.R., Chang K.T. Insulin/IGF signaling-related gene expression in the brain of a sporadic Alzheimer's disease monkey model induced by intracerebroventricular injection of streptozotocin. J. Alzheimers Dis. 2014, 38:251-267.
73. Leelarungrayub D., Saidee K., Pothongsunun P., Pratanaphon S., YanKai A., Bloomer R.J. Six weeks of aerobic dance exercise improves blood oxidative stress status and increases interleukin-2 in previously sedentary women. J. Bodyw. Mov. Ther. 2011, 15:355-362.
74. Lofrumento D.D., Nicolardi G., Cianciulli A., De Nuccio F., La Pesa V., Carofiglio V., Dragone T., Calvello R., Panaro M.A. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. 2014, 20:249-260.
75. Lopez-Sanchez C., Martin-Romero F.J., Sun F., Luis L., Samhan-Arias A.K., Garcia-Martinez V., Gutierrez-Merino C. Blood micromolar concentrations of kaempferol afford protection against ischemia/reperfusion-induced damage in rat brain. Brain Res. 2007, 1182:123-137.
76. Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
77. Madrigal J.L., Moro M.A., Lizasoain I., Lorenzo P., Leza J.C. Stress-induced increase in extracellular sucrose space in rats is mediated by nitric oxide. Brain Res. 2002, 938:87-91.
78. Meulendyke K.A., Pletnikov M.V., Engle E.L., Tarwater P.M., Graham D.R., Zink M.C. Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J. Neuroimmune Pharmacol. 2012, 7:454-464.
79. Militao G.C., Ferreira P.M., de Freitas R.M. Effects of lipoic acid on oxidative stress in rat striatum after pilocarpine-induced seizures. Neurochem. Int. 2010, 56:16-20.
80. Mohagheghi F., Khalaj L., Ahmadiani A., Rahmani B. Gemfibrozil pretreatment affecting antioxidant defense system and inflammatory, but not Nrf-2 signaling pathways resulted in female neuroprotection and male neurotoxicity in the rat models of global cerebral ischemia-reperfusion. Neurotox. Res. 2013, 23:225-237.
81. Mohammad G., Siddiquei M.M., Abu El-Asrar A.M. Poly (ADP-ribose) polymerase mediates diabetes-induced retinal neuropathy. Mediat. Inflamm. 2013, 510451.
82. Moncada S., Bolanos J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 2006, 97:1676-1689.
83. Moszczynska A., Yamamoto B.K. Methamphetamine oxidatively damages parkin and decreases the activity of 26S proteasome in vivo. J. Neurochem. 2011, 116:1005-1017.
84. Niswender K.D., Daws L.C., Avison M.J., Galli A. Insulin regulation of monoamine signaling: pathway to obesity. Neuropsychopharmacology 2011, 36:359-360.
85. O'Donnell V.B., Eiserich J.P., Chumley P.H., Jablonsky M.J., Krishna N.R., Kirk M., Barnes S., Darley-Usmar V.M., Freeman B.A. Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. Chem. Res. Toxicol. 1999, 12:83-92.
86. Pallas M., Porquet D., Vicente A., Sanfeliu C. Resveratrol: new avenues for a natural compound in neuroprotection. Curr. Pharm. Des. 2013, 19:6726-6731.
87. Pangeni R., Sharma S., Mustafa G., Ali J., Baboota S. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. Nanotechnology 2014, 25:485102.
88. Park S., Geddes T.J., Javitch J.A., Kuhn D.M. Dopamine prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide: is nitrotyrosine formation an early step in dopamine neuronal damage?. J. Biol. Chem. 2003, 278:28736-28742.
89. Perez-Asensio F.J., de la Rosa X., Jimenez-Altayo F., Gorina R., Martinez E., Messeguer A., Vila E., Chamorro A., Planas A.M. Antioxidant CR-6 protects against reperfusion injury after a transient episode of focal brain ischemia in rats. J. Cereb. Blood Flow Metab. 2010, 30:638-652.
90. Perry V.H., Holmes C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 2014, 10:217-224.
91. Pieper A.A., Verma A., Zhang J., Snyder S.H. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci. 1999, 20:171-181.
92. Pong K. Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics. Expert. Opin. Biol. Ther. 2003, 3:127-139.
93. Prasad J.E., Kumar B., Andreatta C., Nahreini P., Hanson A.J., Yan X.D., Prasad K.N. Overexpression of alpha-synuclein decreased viability and enhanced sensitivity to prostaglandin E(2), hydrogen peroxide, and a nitric oxide donor in differentiated neuroblastoma cells. J. Neurosci. Res. 2004, 76:415-422.
94. Quincozes-Santos A., Bobermin L.D., Latini A., Wajner M., Souza D.O., Goncalves C.A., Gottfried C. Resveratrol protects C6 astrocyte cell line against hydrogen peroxide-induced oxidative stress through heme oxygenase 1. PLoS One 2013, 8:e64372.
95. Radi R. Peroxynitrite, a stealthy biological oxidant. J. Biol. Chem. 2013, 288:26464-26472.
96. Radi R. Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects. Acc. Chem. Res. 2013, 46:550-559.
97. Rawji K.S., Yong V.W. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin. Dev. Immunol. 2013, 948976.
98. Rebillard A., Lefeuvre-Orfila L., Gueritat J., Cillard J. Prostate cancer and physical activity: adaptive response to oxidative stress. Free Radic. Biol. Med. 2013, 60:115-124.
99. Rege S.D., Kumar S., Wilson D.N., Tamura L., Geetha T., Mathews S.T., Huggins K.W., Broderick T.L., Babu J.R. Resveratrol protects the brain of obese mice from oxidative damage. Oxidative Med. Cell. Longev. 2013, 419092.
100. Rege S.D., Geetha T., Griffin G.D., Broderick T.L., Babu J.R. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front. Aging Neurosci. 2014, 6:218.
101. Rejdak K., Eikelenboom M.J., Petzold A., Thompson E.J., Stelmasiak Z., Lazeron R.H., Barkhof F., Polman C.H., Uitdehaag B.M., Giovannoni G. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004, 63:1439-1445.
102. Rejdak K., Petzold A., Stelmasiak Z., Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult. Scler. (Houndmills Basingstoke Engl.) 2008, 14:59-66.
103. Rodriguez E., Rivera I., Astorga S., Mendoza E., Garcia F., Hernandez-Echeagaray E. Uncoupling oxidative/energy metabolism with low sub chronic doses of 3-nitropropionic acid or iodoacetate in vivo produces striatal cell damage. Int. J. Biol. Sci. 2010, 6:199-212.
104. Roy A., Fung Y.K., Liu X., Pahan K. Up-regulation of microglial CD11b expression by nitric oxide. J. Biol. Chem. 2006, 281:14971-14980.
105. Rubbo H., Radi R. Protein and lipid nitration: role in redox signaling and injury. Biochim. Biophys. Acta 2008, 1780:1318-1324.
106. Rudolph T.K., Freeman B.A. Transduction of redox signaling by electrophile-protein reactions. Sci. Signal. 2009, 2:re7.
107. Ryu J.K., Choi H.B., McLarnon J.G. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006, 141:1835-1848.
108. Sandhir R., Yadav A., Mehrotra A., Sunkaria A., Singh A., Sharma S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease. Neruomol. Med. 2014, 16:106-118.
109. Sarkar S., Korolchuk V.I., Renna M., Imarisio S., Fleming A., Williams A., Garcia-Arencibia M., Rose C., Luo S., Underwood B.R., Kroemer G., O'Kane C.J., Rubinsztein D.C. Complex inhibitory effects of nitric oxide on autophagy. Mol. Cell 2011, 43:19-32.
110. Shchepinov M.S., Chou V.P., Pollock E., Langston J.W., Cantor C.R., Molinari R.J., Manning-Bog A.B. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. Toxicol. Lett. 2011, 207:97-103.
111. Shichiri M. The role of lipid peroxidation in neurological disorders. J. Clin. Biochem. Nutr. 2014, 54:151-160.
112. Shin E.J., Jeong J.H., Bing G., Park E.S., Chae J.S., Yen T.P., Kim W.K., Wie M.B., Jung B.D., Kim H.J., Lee S.Y., Kim H.C. Kainate-induced mitochondrial oxidative stress contributes to hippocampal degeneration in senescence-accelerated mice. Cell. Signal. 2008, 20:645-658.
113. Shin E.J., Ko K.H., Kim W.K., Chae J.S., Yen T.P., Kim H.J., Wie M.B., Kim H.C. Role of glutathione peroxidase in the ontogeny of hippocampal oxidative stress and kainate seizure sensitivity in the genetically epilepsy-prone rats. Neurochem. Int. 2008, 52:1134-1147.
114. Silva-Adaya D., Perez-De La Cruz V., Herrera-Mundo M.N., Mendoza-Macedo K., Villeda-Hernandez J., Binienda Z., Ali S.F., Santamaria A. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J. Neurochem. 2008, 105:677-689.
115. Skundric D.S., Lisak R.P. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp. Diabetes Res. 2003, 4:303-312.
116. Smith K.J., Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002, 1:232-241.
117. Stavniichuk R., Shevalye H., Lupachyk S., Obrosov A., Groves J.T., Obrosova I.G., Yorek M.A. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metab. Res. Rev. 2014, 30:669-678.
118. Stoy N., Mackay G.M., Forrest C.M., Christofides J., Egerton M., Stone T.W., Darlington L.G. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 2005, 93:611-623.
119. Strauss K.I. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav. Immun. 2008, 22:285-298.
120. Strosznajder J.B., Czapski G.A., Adamczyk A., Strosznajder R.P. Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol. Neurobiol. 2012, 46:78-84.
121. Sultana R., Perluigi M., Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 2013, 62:157-169.
122. Suo S., Ishiura S. Dopamine modulates acetylcholine release via octopamine and CREB signaling in Caenorhabditis elegans. PLoS One 2013, 8:e72578.
123. Szumiel I. Autophagy, reactive oxygen species and the fate of mammalian cells. Free Radic. Res. 2011, 45:253-265.
124. Szutowicz A., Bielarczyk H., Jankowska-Kulawy A., Pawelczyk T., Ronowska A. Acetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseases. Neurochem. Res. 2013, 38:1523-1542.
125. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!. Age Ageing 2006, 35:336-338.
126. Tan B., Choi R.H., Chin T.J., Kaur C., Ling E.A. Manipulation of microglial activity as a therapy for Alzheimer's disease. Front. Biosci. (Schol. Ed.) 2012, 4:1402-1412.
127. Thomas B., Beal M.F. Parkinson's disease. Hum. Mol. Genet. 2007, 16(2):R183-R194.
128. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. FASEB J. 2006, 20:515-517.
129. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 2008, 105:605-616.
130. Ting J.T., Kelley B.G., Lambert T.J., Cook D.G., Sullivan J.M. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:353-358.
131. Trudel S., Trecherel E., Gomila C., Peltier M., Aubignat M., Gubler B., Morliere P., Heard J.M., Ausseil J. Oxidative stress is independent of inflammation in the neurodegenerative sanfilippo syndrome type B. J. Neurosci. Res. 2014, 93(3):424-432.
132. Tsang A.H., Lee Y.I., Ko H.S., Savitt J.M., Pletnikova O., Troncoso J.C., Dawson V.L., Dawson T.M., Chung K.K. S-Nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4900-4905.
133. Tully M., Shi R. New insights in the pathogenesis of multiple sclerosis-role of acrolein in neuronal and myelin damage. Int. J. Mol. Sci. 2013, 14:20037-20047.
134. Turner B.J., Cheah I.K., Macfarlane K.J., Lopes E.C., Petratos S., Langford S.J., Cheema S.S. Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J. Neurochem. 2003, 87:752-763.
135. Turunc Bayrakdar E., Uyanikgil Y., Kanit L., Koylu E., Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer's disease. Free Radic. Res. 2014, 48:146-158.
136. Uehara T., Nakamura T., Yao D., Shi Z.Q., Gu Z., Ma Y., Masliah E., Nomura Y., Lipton S.A. S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006, 441:513-517.
137. Umegaki H. Neurodegeneration in diabetes mellitus. Adv. Exp. Med. Biol. 2012, 724:258-265.
138. Vareniuk I., Pavlov I.A., Drel V.R., Lyzogubov V.V., Ilnytska O., Bell S.R., Tibrewala J., Groves J.T., Obrosova I.G. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp. Neurol. 2007, 205:425-436.
139. Vareniuk I., Pavlov I.A., Obrosova I.G. Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes. Diabetologia 2008, 51:2126-2133.
140. Vareniuk I., Pacher P., Pavlov I.A., Drel V.R., Obrosova I.G. Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency. Int. J. Mol. Med. 2009, 23:571-580.
141. Villani G.R., Di Domenico C., Musella A., Cecere F., Di Napoli D., Di Natale P. Mucopolysaccharidosis IIIB: oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Res. 2009, 1279:99-108.
142. Vinik A.I., Nevoret M.L., Casellini C., Parson H. Diabetic neuropathy. Endocrinol. Metab. Clin. N. Am. 2013, 42:747-787.
143. Wang Y.Q., Bian G.L., Bai Y., Cao R., Chen L.W. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats. Neurochem. Int. 2008, 53:56-62.
144. Williams J.M., Owens W.A., Turner G.H., Saunders C., Dipace C., Blakely R.D., France C.P., Gore J.C., Daws L.C., Avison M.J., Galli A. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol. 2007, 5:e274.
145. Winterbourn C.C. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol. Lett. 1995, 82-83:969-974.
146. Wong E.S., Tan J.M., Wang C., Zhang Z., Tay S.P., Zaiden N., Ko H.S., Dawson V.L., Dawson T.M., Lim K.L. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem. 2007, 282:12310-12318.
147. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. Off. J. Soc. Neurosci. 2002, 22:1763-1771.
148. Yenari M.A., Kauppinen T.M., Swanson R.A. Microglial activation in stroke: therapeutic targets. Neurotherapeutics 2010, 7:378-391.
149. Yeo W.S., Kim Y.J., Kabir M.H., Kang J.W., Kim K.P. Mass spectrometric analysis of protein tyrosine nitration in aging and neurodegenerative diseases. Mass Spectrom. Rev. 2014, 34(2):166-183.
150. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15769-15774.
151. Zahid M., Saeed M., Yang L., Beseler C., Rogan E., Cavalieri E.L. Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease. IUBMB life 2011, 63:1087-1093.
152. Zaja-Milatovic S., Gupta R.C., Aschner M., Montine T.J., Milatovic D. Pharmacologic suppression of oxidative damage and dendritic degeneration following kainic acid-induced excitotoxicity in mouse cerebrum. Neurotoxicology 2008, 29:621-627.
153. Zhang L., Zhou F.M., Dani J.A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 2004, 66:538-544.
154. Zhang F., Shi J.S., Zhou H., Wilson B., Hong J.S., Gao H.M. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol. Pharmacol. 2010, 78:466-477.
155. Zhou J., Zhou S. Inflammation: therapeutic targets for diabetic neuropathy. Mol. Neurobiol. 2014, 49:536-546.
156. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.